Download Leseprobe.
Download Leseprobe.
Download Leseprobe.
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
Studienverzeichnis<br />
Studienname Beschreibung/Titel Seitenzahl<br />
ADAPT<br />
BEATRICE<br />
A Prospective, Randomized Multicenter, Open-label Comparison of<br />
Preoperative Combination of Trastuzumab and Pertuzumab With or<br />
Without Concurrent Taxane Chemotherapy Given for Twelve Weeks<br />
in Patients With Operable HER2+/HR- Breast Cancer Within the<br />
ADAPT Protocol<br />
BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy<br />
in Triple Negative Breast Cancer.<br />
28<br />
168<br />
Chemo-N0 Prognostic and Predictive Impact of uPA/PAI-1 27<br />
GEICAM/9906<br />
GeparSIXTO<br />
MINDACT<br />
MIRROR<br />
NCIC-CTG-MA.12<br />
NCIC-CTG-MA.5<br />
NCT00337103<br />
NNBC-3<br />
NSABP-B46<br />
TAILORx<br />
Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) Versus FEC Plus<br />
Paclitaxel as Adjuvant Treatment for Node Positive Breast Cancer<br />
Patients<br />
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative<br />
and HER2-positive Early Breast Cancer<br />
Genetic Testing or Clinical Assessment in Determining the Need for<br />
Chemotherapy in Women With Breast Cancer That Involves No More<br />
Than 3 Lymph Nodes<br />
Micrometastases and isolated tumor cells: relevant and robust or<br />
rubbish?<br />
Prognostic and Predictive Impact of Intrinsic Biological Classification<br />
by Immunohistochemistry (IHC) and QPCR for Adjuvant Tamoxifen in<br />
Pre-Menopausal Breast Cancer<br />
Phase III Adjuvant Chemotherapy with Intensive CEF (CTX/EPI/5-FU)<br />
vs Standard CMF (CTX/MTX/5-FU) in Premenopausal Patients with<br />
Carcinoma of the Breast with Positive Axillary Nodes<br />
A Phase III, open-label, randomized, multicenter study of eribulin<br />
mesylate versus capecitabine in patients with locally advanced or<br />
metastatic breast cancer previously treated with anthracyclines and<br />
taxanes<br />
6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to<br />
3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients<br />
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab<br />
to TC Alone and to TAC for Women With Node-Positive or High-Risk<br />
Node-Negative, HER2-Negative Breast Cancer<br />
Hormone Therapy With or Without Combination Chemotherapy in<br />
Treating Women Who Have Undergone Surgery for Node-Negative<br />
Breast Cancer (The TAILORx Trial)<br />
23<br />
173<br />
28<br />
20<br />
22<br />
22<br />
170<br />
27<br />
74<br />
28<br />
26 Studienverzeichnis
Change language